FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912991002> ?p ?o ?g. }

• W2912991002 endingPage "189" @default.
• W2912991002 startingPage "180" @default.
• W2912991002 abstract "Inflammation and oxidative stress are the two processes crucial in atherogenesis. Platelet-activating factor acetylhydrolase (PAF-AH), a plasma lipoprotein-associated enzyme, degrades pro-inflammatory lipids generated within oxidatively modified lipoproteins. Extensive evidence shows that incretin-based drugs, a new class of anti-diabetic agents, can provide cardiovascular protection that cannot be attributed to their glucose-lowering effects. The present study was undertaken to determine whether the antiatherogenic effects of the GLP-1(glucagon-like peptide-1) receptor agonist (exenatide) and DPP-4(dipeptidyl peptidase-4) inhibitors (sitagliptin) may occur via the regulation of platelet-activating factor acetylhydrolase (PAF-AH) activity/mass and inhibition of low-density lipoprotein (LDL) oxidation in the fructose-fed rats. Normal and fructose-fed rats (8 wk) were treated (4 wk) with sitagliptin (5 and 10 mg/kg p.o.) or with exenatide (5 and 10 µg/kg, s.c.). Plasma PAF-AH activity and phosphatidylcholine (PC) concentration were measured colorimetrically. Plasma PAF-AH concentration, oxidized LDL (oxLDL), hexanoyl-Lys adduct (HEL), lyso-PC, apolipoprotein A-I (apoA-I), apoB, platelet-activating factor (PAF), monocyte chemoattractant protein-1 (MCP-1) and endothelin-1 (ET-1) were measured by ELISA. The four-week exenatide (5 µg/kg, sc.) treatment of fructose fed-rats significantly increased plasma PAF-AH activity (+33%, P < 0.001) and decreased the level of circulating oxLDL (-42%, P < 0.05) and MCP-1 (-23%, P < 0.01). These changes were accompanied by the decrease in plasma PC/lyso-PC (-47%, P < 0.001) and apoB/apoA-I ratio (-75%, P < 0.001). The effect of exenatide on enzyme activity was associated with only a minor effect on metabolic parameters and was independent of weight reduction. Exenatide but not sitagliptin inhibits oxidative modification of LDL probably due to favorable effect on plasma PAF-AH activity." @default.
• W2912991002 created "2019-02-21" @default.
• W2912991002 creator A5007280371 @default.
• W2912991002 creator A5049277205 @default.
• W2912991002 creator A5049608493 @default.
• W2912991002 creator A5056739575 @default.
• W2912991002 creator A5063876935 @default.
• W2912991002 creator A5067941041 @default.
• W2912991002 creator A5068022302 @default.
• W2912991002 date "2019-05-01" @default.
• W2912991002 modified "2023-10-16" @default.
• W2912991002 title "The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats" @default.
• W2912991002 cites W1589395925 @default.
• W2912991002 cites W1601746604 @default.
• W2912991002 cites W1776504557 @default.
• W2912991002 cites W1858538809 @default.
• W2912991002 cites W1969184047 @default.
• W2912991002 cites W1972072206 @default.
• W2912991002 cites W2000976083 @default.
• W2912991002 cites W2019448874 @default.
• W2912991002 cites W2020435303 @default.
• W2912991002 cites W2021718697 @default.
• W2912991002 cites W2023030159 @default.
• W2912991002 cites W2028515800 @default.
• W2912991002 cites W2028886298 @default.
• W2912991002 cites W2028976029 @default.
• W2912991002 cites W2029071587 @default.
• W2912991002 cites W2030140594 @default.
• W2912991002 cites W2031438601 @default.
• W2912991002 cites W2033892901 @default.
• W2912991002 cites W2034454243 @default.
• W2912991002 cites W2039464415 @default.
• W2912991002 cites W2044109232 @default.
• W2912991002 cites W2046535650 @default.
• W2912991002 cites W2049098647 @default.
• W2912991002 cites W2055611619 @default.
• W2912991002 cites W2057809540 @default.
• W2912991002 cites W2060949491 @default.
• W2912991002 cites W2063182530 @default.
• W2912991002 cites W2068361785 @default.
• W2912991002 cites W2074209817 @default.
• W2912991002 cites W2075567076 @default.
• W2912991002 cites W2075972707 @default.
• W2912991002 cites W2080486016 @default.
• W2912991002 cites W2084618648 @default.
• W2912991002 cites W2086868800 @default.
• W2912991002 cites W2096739965 @default.
• W2912991002 cites W2106690226 @default.
• W2912991002 cites W2112957187 @default.
• W2912991002 cites W2116409842 @default.
• W2912991002 cites W2119382976 @default.
• W2912991002 cites W2120131412 @default.
• W2912991002 cites W2122626660 @default.
• W2912991002 cites W2126021826 @default.
• W2912991002 cites W2128077095 @default.
• W2912991002 cites W2130583827 @default.
• W2912991002 cites W2133336537 @default.
• W2912991002 cites W2136112044 @default.
• W2912991002 cites W2142097676 @default.
• W2912991002 cites W2147093462 @default.
• W2912991002 cites W2158820616 @default.
• W2912991002 cites W2158822657 @default.
• W2912991002 cites W2159316083 @default.
• W2912991002 cites W2161564579 @default.
• W2912991002 cites W2161872363 @default.
• W2912991002 cites W2166259521 @default.
• W2912991002 cites W2283083940 @default.
• W2912991002 cites W2492766423 @default.
• W2912991002 cites W2496216273 @default.
• W2912991002 cites W2762054879 @default.
• W2912991002 cites W2782198850 @default.
• W2912991002 cites W4232073522 @default.
• W2912991002 doi "https://doi.org/10.1016/j.ejphar.2019.02.014" @default.
• W2912991002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30768981" @default.
• W2912991002 hasPublicationYear "2019" @default.
• W2912991002 type Work @default.
• W2912991002 sameAs 2912991002 @default.
• W2912991002 citedByCount "6" @default.
• W2912991002 countsByYear W29129910022019 @default.
• W2912991002 countsByYear W29129910022020 @default.
• W2912991002 countsByYear W29129910022021 @default.
• W2912991002 countsByYear W29129910022022 @default.
• W2912991002 countsByYear W29129910022023 @default.
• W2912991002 crossrefType "journal-article" @default.
• W2912991002 hasAuthorship W2912991002A5007280371 @default.
• W2912991002 hasAuthorship W2912991002A5049277205 @default.
• W2912991002 hasAuthorship W2912991002A5049608493 @default.
• W2912991002 hasAuthorship W2912991002A5056739575 @default.
• W2912991002 hasAuthorship W2912991002A5063876935 @default.
• W2912991002 hasAuthorship W2912991002A5067941041 @default.
• W2912991002 hasAuthorship W2912991002A5068022302 @default.
• W2912991002 hasConcept C126322002 @default.
• W2912991002 hasConcept C134018914 @default.
• W2912991002 hasConcept C185592680 @default.
• W2912991002 hasConcept C2776398474 @default.
• W2912991002 hasConcept C2776970464 @default.
• W2912991002 hasConcept C2777180221 @default.
• W2912991002 hasConcept C2778163477 @default.

• next